Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B

Study Summary

A Phase 1/2, open-label, dose-finding safety study of single ascending doses of DTX101 in adult males with moderate/severe to severe hemophilia B.

Interventions

Study Locations

Facility	City	State	Country
Arkansas Children's Hospital	Little Rock	Arkansas	United States
Orthopaedic Institute for Children	Los Angeles	California	United States
University of Florida	Gainesville	Florida	United States
Boston Children's Hospital	Boston	Massachusetts	United States
University of Michigan Hospital and Health Systems, Michigan Clinical Research Unit	Ann Arbor	Michigan	United States
Vanderbilt Hemostasis-Thrombosis Clinic	Nashville	Tennessee	United States
Specialized Hospital for Active Treatment for Hematological Disease	Sofia		Bulgaria
Basingstoke and North Hampshire Hospital, Haemophilia, Haemostasis and Thrombosis Centre	Basingstoke	Hampshire	United Kingdom
The Christie NHS Foundation Trust	Manchester		United Kingdom

Official Trial Information

View on ClinicalTrials.gov